Below is a list of current clinical trials open to enrollment at New England Cancer Specialists. Trials can open and close very quickly, depending on the phase of the study, responses from patients already enrolled, or FDA requests.
We try to have a trial available in every disease area, but this isn’t always possible. If you don’t see a study that might be right for you, please ask your doctor or nurse.
For a full list of clinical trials across the U.S., visit www.clinicaltrials.gov.
If you have questions or wish to speak with someone from our research department, contact us
T-1-19 (MK7902-011) A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011). Learn more
T-2-19 (MK3475-866) A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer. Learn more
Brain EV-2-16 (OT-15-001) STELLAR
A Phase III, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma that Progress/Recur after Irradiation and Adjuvant Temozolomide Chemotherapy. Learn more
Breast, AO11401 (BWEL)
Randomized Phase III Trial Evaluating The Role Of Weight Loss in Adjuvant Treatment Of Overweight And Obese Women With Early Breast Cancer. Learn more
Breast, CB-2-17 (AFT-38/PATINA) A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer. Learn more
Breast, CB-3-17 (AFT-25/COMET) Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase II Prospective Trial. Learn more Patient Brochure
Breast, W-1-19 (EMERALD) Elacestrant Monotherapy vs. Standard of Care for Treatment of Patients with ER+Her2 – Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-Lable Active-Controlled, Multicenter Trial.
Breast, EA1181 (CompassHER2-pCR) Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer)
S1418: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast cancer with ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy.
Genomics, T-3-17 (JAX2)
A Study of Oncology Clinician And Patient Experiences With Clinical Genomics in Maine. Learn more
Genomics, EAY131 (MATCH)
Molecular Analysis for Therapy Choice. Learn more
Genomics, PICI An Exploratory Biomarker Study of Checkpoint Inhibitors (PD-1, PD-L1, and CTLA-4) used as Monotherapy or in Combination in Patients with Cancer.
Liver, DU-3-20 (WO41535) A Phase III, Multicenter, Randomized, Open-Label Study of Atezolizumab (ANTI-PD-L1 Antibody) Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients with Hepatocellualar Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
Lung, Alliance A081105
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC). Learn more
Lung, Alliance A151216
Adjuvent Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST). Learn more
Lung, ECOG E4512
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein. Learn more
Lung, EV-2-19 (MRT516-005)
A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy.
Lung, GO41854 Skyscraper03 (T-2-20) A Phase III, Open-label, Randomized Study of Atezolizumab and Tiragolumab Compared with Durvalumab in Patients with Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer who have not Progressed After Concurrent Platinum-based Chemoradiation
Lung, T-1-20 (GO41767) A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide with or without Tiragolumab (Anti-Tigit Antibody) in Patients with Untreated Extensive-Stage Small Cell Lung Cancer
Pancreatic, DU-1-20 (D-US-60010-001) An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas
Genomics, PICI An Exploratory Biomarker Study of Checkpoint Inhibitors (PD-1, PD-L1, and CTLA-4) used as Monotherapy or in Combination in Patients with Cancer.
T-3-19 (XL184-313) A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk
NECS Providers - For more information on these clinical trials, visit (log-in required): NECS Clinical Trials
